These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31. Tan-Chiu E; Yothers G; Romond E; Geyer CE; Ewer M; Keefe D; Shannon RP; Swain SM; Brown A; Fehrenbacher L; Vogel VG; Seay TE; Rastogi P; Mamounas EP; Wolmark N; Bryant J J Clin Oncol; 2005 Nov; 23(31):7811-9. PubMed ID: 16258083 [TBL] [Abstract][Full Text] [Related]
6. Effect of addition of adjuvant paclitaxel on radiotherapy delivery and locoregional control of node-positive breast cancer: cancer and leukemia group B 9344. Sartor CI; Peterson BL; Woolf S; Fitzgerald TJ; Laurie F; Turrisi AJ; Bogart J; Henderson IC; Norton L J Clin Oncol; 2005 Jan; 23(1):30-40. PubMed ID: 15545661 [TBL] [Abstract][Full Text] [Related]
7. Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial. Perez EA; Suman VJ; Davidson NE; Sledge GW; Kaufman PA; Hudis CA; Martino S; Gralow JR; Dakhil SR; Ingle JN; Winer EP; Gelmon KA; Gersh BJ; Jaffe AS; Rodeheffer RJ J Clin Oncol; 2008 Mar; 26(8):1231-8. PubMed ID: 18250349 [TBL] [Abstract][Full Text] [Related]
8. Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41): an open-label, randomised phase 3 trial. Robidoux A; Tang G; Rastogi P; Geyer CE; Azar CA; Atkins JN; Fehrenbacher L; Bear HD; Baez-Diaz L; Sarwar S; Margolese RG; Farrar WB; Brufsky AM; Shibata HR; Bandos H; Paik S; Costantino JP; Swain SM; Mamounas EP; Wolmark N Lancet Oncol; 2013 Nov; 14(12):1183-92. PubMed ID: 24095300 [TBL] [Abstract][Full Text] [Related]
10. Effect of doxorubicin plus cyclophosphamide on left ventricular ejection fraction in patients with breast cancer in the North Central Cancer Treatment Group N9831 Intergroup Adjuvant Trial. Perez EA; Suman VJ; Davidson NE; Kaufman PA; Martino S; Dakhil SR; Ingle JN; Rodeheffer RJ; Gersh BJ; Jaffe AS J Clin Oncol; 2004 Sep; 22(18):3700-4. PubMed ID: 15365066 [TBL] [Abstract][Full Text] [Related]
11. [Breast cancer: HER2 changes one's cards on the table]. Lopez M Clin Ter; 2005; 156(5):255-62. PubMed ID: 16382976 [TBL] [Abstract][Full Text] [Related]
12. Impact of PTEN protein expression on benefit from adjuvant trastuzumab in early-stage human epidermal growth factor receptor 2-positive breast cancer in the North Central Cancer Treatment Group N9831 trial. Perez EA; Dueck AC; McCullough AE; Chen B; Geiger XJ; Jenkins RB; Lingle WL; Davidson NE; Martino S; Kaufman PA; Kutteh LA; Sledge GW; Harris LN; Gralow JR; Reinholz MM J Clin Oncol; 2013 Jun; 31(17):2115-22. PubMed ID: 23650412 [TBL] [Abstract][Full Text] [Related]
13. Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer. Tolaney SM; Barry WT; Dang CT; Yardley DA; Moy B; Marcom PK; Albain KS; Rugo HS; Ellis M; Shapira I; Wolff AC; Carey LA; Overmoyer BA; Partridge AH; Guo H; Hudis CA; Krop IE; Burstein HJ; Winer EP N Engl J Med; 2015 Jan; 372(2):134-41. PubMed ID: 25564897 [TBL] [Abstract][Full Text] [Related]
14. Association of Stromal Tumor-Infiltrating Lymphocytes With Recurrence-Free Survival in the N9831 Adjuvant Trial in Patients With Early-Stage HER2-Positive Breast Cancer. Perez EA; Ballman KV; Tenner KS; Thompson EA; Badve SS; Bailey H; Baehner FL JAMA Oncol; 2016 Jan; 2(1):56-64. PubMed ID: 26469139 [TBL] [Abstract][Full Text] [Related]
15. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort. Gianni L; Eiermann W; Semiglazov V; Manikhas A; Lluch A; Tjulandin S; Zambetti M; Vazquez F; Byakhow M; Lichinitser M; Climent MA; Ciruelos E; Ojeda B; Mansutti M; Bozhok A; Baronio R; Feyereislova A; Barton C; Valagussa P; Baselga J Lancet; 2010 Jan; 375(9712):377-84. PubMed ID: 20113825 [TBL] [Abstract][Full Text] [Related]
16. Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28. Mamounas EP; Bryant J; Lembersky B; Fehrenbacher L; Sedlacek SM; Fisher B; Wickerham DL; Yothers G; Soran A; Wolmark N J Clin Oncol; 2005 Jun; 23(16):3686-96. PubMed ID: 15897552 [TBL] [Abstract][Full Text] [Related]
17. C-MYC alterations and association with patient outcome in early-stage HER2-positive breast cancer from the north central cancer treatment group N9831 adjuvant trastuzumab trial. Perez EA; Jenkins RB; Dueck AC; Wiktor AE; Bedroske PP; Anderson SK; Ketterling RP; Sukov WR; Kanehira K; Chen B; Geiger XJ; Andorfer CA; McCullough AE; Davidson NE; Martino S; Sledge GW; Kaufman PA; Kutteh LA; Gralow JR; Harris LN; Ingle JN; Lingle WL; Reinholz MM J Clin Oncol; 2011 Feb; 29(6):651-9. PubMed ID: 21245420 [TBL] [Abstract][Full Text] [Related]
18. Prospective randomized trial of 5-fluorouracil, doxorubicin, and cyclophosphamide (FAC) versus paclitaxel and FAC (TFAC) in patients with operable breast cancer: impact of taxane chemotherapy on locoregional control. Albert JM; Buzdar AU; Guzman R; Allen PK; Strom EA; Perkins GH; Woodward WA; Hoffman KE; Tereffe W; Hunt KK; Buchholz TA; Oh JL Breast Cancer Res Treat; 2011 Jul; 128(2):421-7. PubMed ID: 21553292 [TBL] [Abstract][Full Text] [Related]
19. Adjuvant dose-dense doxorubicin plus cyclophosphamide followed by dose-dense nab-paclitaxel is safe in women with early-stage breast cancer: a pilot study. Robert N; Krekow L; Stokoe C; Clawson A; Iglesias J; O'Shaughnessy J Breast Cancer Res Treat; 2011 Jan; 125(1):115-20. PubMed ID: 20945091 [TBL] [Abstract][Full Text] [Related]
20. Incidence of Late Relapses in Patients With HER2-Positive Breast Cancer Receiving Adjuvant Trastuzumab: Combined Analysis of NCCTG N9831 (Alliance) and NRG Oncology/NSABP B-31. Chumsri S; Li Z; Serie DJ; Mashadi-Hossein A; Colon-Otero G; Song N; Pogue-Geile KL; Gavin PG; Paik S; Moreno-Aspitia A; Perez EA; Thompson EA J Clin Oncol; 2019 Dec; 37(35):3425-3435. PubMed ID: 31622131 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]